PATENT CLAIM ANALYSIS

Application Number: 15916953
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

Claim (Index 7):
The method of  claim 5 , wherein the outer cannula comprises a side aperture, and further wherein the tumor cells are drawn into the side aperture by electronically controlled variable suction.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 90.0
- Lexical Diversity: 1.53947
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15917050', '15867000', '15095877', '12582013', '14775667']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8135973844739078
- 35 USC 102 Novelty (BERT): 0.6406679248455278
- Combined Prediction Score: 0.7963044385110699
- Mean Citation Score: 450.281174
- Max Citation Score: 737.1239999999997
- Similarity Product: 541.953898246765

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test